Heron Therapeutics (HRTX) Cash from Investing Activities (2010 - 2026)

Heron Therapeutics (HRTX) has 17 years of Cash from Investing Activities data on file, last reported at -$939000.0 in Q1 2026.

• Quarterly Cash from Investing Activities fell 141.31% year-over-year to -$939000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.8 million (down 35.07% YoY) and the FY2025 annual result came in at $16.0 million, down 14.45% from the prior year.
• Cash from Investing Activities grew to -$939000.0 in Q1 2026, from -$5.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $36.8 million in Q1 2023 to a low of -$36.0 million in Q3 2022.
• A 5-year average of $2.9 million and a median of $2.3 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 351.98% — and 2023, when it sank 537.21%.
• Tracing HRTX's Cash from Investing Activities over 5 years: stood at $2.0 million in 2022, then slumped by 537.21% to -$8.8 million in 2023, then surged by 229.22% to $11.4 million in 2024, then sank by 147.78% to -$5.5 million in 2025, then surged by 82.79% to -$939000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$939000.0 (Q1 2026), -$5.5 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.